Search

Your search keyword '"Lowe SH"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Lowe SH" Remove constraint Author: "Lowe SH" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
41 results on '"Lowe SH"'

Search Results

1. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

2. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy

5. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

7. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

8. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

9. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

10. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

11. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

12. Erythrocyte Inosine Triphosphatase Activity Is Decreased in HIV-Seropositive Individuals

13. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes

14. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

15. Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

16. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

17. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy.

18. Metabolic events in HIV-infected patients using abacavir are associated with erythrocyte inosine triphosphatase activity.

19. Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy.

20. Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV.

21. Inosine Triphosphate Pyrophosphohydrolase Expression: Decreased in Leukocytes of HIV-Infected Patients Using Combination Antiretroviral Therapy.

22. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

23. No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis.

24. Successful treatment of neuroborreliosis in an HIV patient with simultaneous Borrelia, HIV-1 and Epstein-Barr virus genomes in liquor.

25. Improving sexual health for HIV patients by providing a combination of integrated public health and hospital care services; a one-group pre- and post test intervention comparison.

26. Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection.

27. Erythrocyte inosine triphosphatase activity is decreased in HIV-seropositive individuals.

28. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.

29. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).

30. No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.

31. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

32. Semen parameters of a semen donor before and after infection with human immunodeficiency virus type 1: case report.

33. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome.

34. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.

35. Does highly active antiretroviral therapy induce sickle cell crises?

36. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.

37. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.

38. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.

39. Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.

40. Parathyroid gland calcium receptor mRNA levels are unaffected by chronic renal insufficiency or low dietary calcium in rats.

Catalog

Books, media, physical & digital resources